IHS Chemical Week

Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals

Pfizer and Ranbaxy Settle Lipitor Patent Dispute

11:37 AM MDT | June 23, 2008 | Deepti Ramesh

Pfizer (New York) and Ranbaxy Laboratories Ltd. (Gurgaon) say they have settled their patent dispute involving Pfizer’s Lipitor, the largest selling cholesterol-lowering drug worldwide with sales of $12.7 billion. The agreement provides Ranbaxy with a license to sell Atorvastatin, the generic version of Lipitor, in the U.S. starting November 30, 2011, and in Australia, Belgium, Canada, Germany, Italy, the Netherlands, and Sweden starting at various dates, the firms say. The agreement follows unconfirmed media reports earlier this month regarding the...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa